Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.

Cortesi L, Razzaboni E, Toss A, De Matteis E, Marchi I, Medici V, Tazzioli G, Andreotti A, De Santis G, Pignatti M, Federico M.

Ann Oncol. 2014 Jan;25(1):57-63. doi: 10.1093/annonc/mdt422. Epub 2013 Nov 24.

2.

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.

Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.

3.

Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.

Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Hillegersberg R, Rutgers EJ, Aaronson NK.

BMC Cancer. 2011 Jan 10;11:6. doi: 10.1186/1471-2407-11-6.

4.

Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.

Wevers MR, Aaronson NK, Verhoef S, Bleiker EM, Hahn DE, Kuenen MA, van der Sanden-Melis J, Brouwer T, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Witkamp AJ, Rutgers EJ, Ausems MG.

Br J Cancer. 2014 Feb 18;110(4):1081-7. doi: 10.1038/bjc.2013.805. Epub 2014 Jan 14.

5.

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.

Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C.

J Clin Oncol. 2004 May 15;22(10):1823-9. Epub 2004 Apr 5.

6.

Breast cancer after bilateral risk-reducing mastectomy.

Skytte AB, Crüger D, Gerster M, Laenkholm AV, Lang C, Brøndum-Nielsen K, Andersen MK, Sunde L, Kølvraa S, Gerdes AM.

Clin Genet. 2011 May;79(5):431-7. doi: 10.1111/j.1399-0004.2010.01604.x. Epub 2011 Jan 4.

PMID:
21199491
7.

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Kiely BE, Jenkins MA, McKinley JM, Friedlander ML, Weideman P, Milne RL, McLachlan SA, Hopper JL, Phillips KA.

Breast Cancer Res Treat. 2010 Apr;120(3):715-23. doi: 10.1007/s10549-009-0497-8. Epub 2009 Aug 11. Erratum in: Breast Cancer Res Treat. 2010 Apr;120(3):725-6.

PMID:
19669874
8.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
9.

Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.

van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.

Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.

PMID:
24268650
10.

Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.

Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW.

Breast J. 2004 Nov-Dec;10(6):475-80.

PMID:
15569201
11.

Risk management options elected by women after testing positive for a BRCA mutation.

Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.

Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.

PMID:
24355485
12.

Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.

Wevers MR, Hahn DE, Verhoef S, Bolhaar MD, Ausems MG, Aaronson NK, Bleiker EM.

Patient Educ Couns. 2012 Oct;89(1):89-95. doi: 10.1016/j.pec.2012.03.019. Epub 2012 Apr 28.

13.

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.

Breast Cancer Res Treat. 2002 May;73(2):97-112.

PMID:
12088120
14.

BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.

Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S.

Oncol Rep. 2010 Dec;24(6):1661-7.

PMID:
21042765
15.

Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.

Laitman Y, Vaisman Y, Feldman D, Helpman L, Gitly M, Paluch Shimon S, Berger R, Cohen L, Narod SA, Friedman E.

Clin Genet. 2014 Jan;85(1):68-71. doi: 10.1111/cge.12149. Epub 2013 Apr 9.

PMID:
23517234
16.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
17.

Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.

Schwartz MD, Valdimarsdottir HB, DeMarco TA, Peshkin BN, Lawrence W, Rispoli J, Brown K, Isaacs C, O'Neill S, Shelby R, Grumet SC, McGovern MM, Garnett S, Bremer H, Leaman S, O'Mara K, Kelleher S, Komaridis K.

Health Psychol. 2009 Jan;28(1):11-9. doi: 10.1037/a0013147.

18.

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.

Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group.

BMC Cancer. 2012 Jul 28;12:320. doi: 10.1186/1471-2407-12-320.

19.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.

J Clin Oncol. 2004 Mar 15;22(6):1055-62. Epub 2004 Feb 23.

20.

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K.

J Clin Oncol. 2002 Mar 1;20(5):1260-8.

PMID:
11870168
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk